1. Home
  2. CPB vs BLTE Comparison

CPB vs BLTE Comparison

Compare CPB & BLTE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Campbell Soup Company

CPB

Campbell Soup Company

N/A

Current Price

$21.30

Market Cap

7.0B

ML Signal

N/A

Logo Belite Bio Inc

BLTE

Belite Bio Inc

N/A

Current Price

$169.01

Market Cap

6.0B

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
CPB
BLTE
Founded
1869
2018
Country
United States
United States
Employees
N/A
N/A
Industry
Packaged Foods
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Staples
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
7.0B
6.0B
IPO Year
1994
2021

Fundamental Metrics

Financial Performance
Metric
CPB
BLTE
Price
$21.30
$169.01
Analyst Decision
Hold
Strong Buy
Analyst Count
18
7
Target Price
$26.06
$198.00
AVG Volume (30 Days)
7.7M
175.7K
Earning Date
06-01-2026
05-08-2026
Dividend Yield
7.63%
N/A
EPS Growth
6.35
N/A
EPS
1.55
N/A
Revenue
$10,253,000,000.00
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
$0.11
$492.11
P/E Ratio
$13.66
N/A
Revenue Growth
6.40
N/A
52 Week Low
$19.56
$68.21
52 Week High
$34.18
$200.00

Technical Indicators

Market Signals
Indicator
CPB
BLTE
Relative Strength Index (RSI) 43.91 52.79
Support Level $21.35 $167.80
Resistance Level $23.45 $172.02
Average True Range (ATR) 0.66 8.32
MACD -0.15 -0.10
Stochastic Oscillator 29.35 43.49

Price Performance

Historical Comparison
CPB
BLTE

About CPB Campbell Soup Company

Over the past 150-plus years, Campbell's has evolved into a leading domestic packaged food manufacturer, with a portfolio that extends beyond its iconic red-and-white labeled canned soup. In fiscal 2025 (July year-end), snacks accounted for 43% of its revenue, followed by soup (27%), other simple meals (23%), and beverages (7%). Beyond its namesake, its brands include Pepperidge Farm, Goldfish, Snyder's of Hanover, Swanson, Pacific Foods, Prego, Pace, V8, and, most recently, Rao's (a deal that closed in 2024). Around 90% of its revenue results from the US and the remainder from Canada and Latin America.

About BLTE Belite Bio Inc

Belite Bio Inc is a clinical stage biopharmaceutical drug development company focused on advancing novel therapeutics targeting degenerative retinal diseases which have unmet medical need such as Geographic Atrophy (GA), the late atrophic (dry) form of age-related macular degeneration (AMD), and Stargardt disease type 1 (STGD1). In addition to its product candidate (tinlarebant) which is intended for the treatment of GA and STGD1, its drug development pipeline also includes a small molecule, orally administered compound, LBS-009, which is intended for the treatment of metabolic diseases such as non-alcoholic fatty liver disease (NAFLD), nonalcoholic steatohepatitis (NASH), type 2 diabetes (T2D), and gout.

Share on Social Networks: